|
|
| March 14, 2010: Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiov |
At ACC 2010, Dr. Henry Ginsberg presents: Effects of Combination Lipid Therapy on
Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular
Risk in Diabetes (ACCORD) Lipid Trial.
Dr. Ginsberg reports receiving:
- Consulting fees from Merck, Merck Schering Plough, Bristol-Myers Squibb, AstraZeneca,
Abbott, Roche, Isis/Genzyme, GlaxoSmithKline, Novartis, Pfizer, and Regeneron/
SanofiAventis.
- Grant support from Merck, ISIS/Genzyme, Roche, and AstraZeneca.
[ Download video ] |
|
No comments have been submitted
|